Commercialisation of Remplir™ into US Market Continues to Build Momentum
Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir™ in the US.
August 13, 2025
Orthocell Announces Changes to its Board of Directors
Orthocell has today announced some important changes to its Board of Directors.
July 25, 2025
First US Sales Revenue from Remplir™
Orthocell has today reached a critical milestone in the commercialisation of Remplir™ in the US$1.6 Billion US market, recording its first sales revenue from the nerve repair product in the US.
July 10, 2025
OCC Quarterly Report | Quarter ended 30 June 2025
Orthocell has today released its Quarterly Report for the period ended 30 June 2025.
July 9, 2025
Orthocell Achieves a Record $2.73m in Revenue for June Quarter
Orthocell has announced record quarterly revenue of $2.73 million for the June quarter – our fifth consecutive quarter of record revenue growth.
July 1, 2025
First US Surgical Use of Remplir™
Orthocell recorded first use of Remplir™ in the US overnight, which is an important step in establishing surgical experience and knowledge of the product.
June 27, 2025
Breakthrough Study Confirms Remplir™ Superiority Over Standard US Nerve Repair Technique
Orthocell has today announced interim results from a new study demonstrating that Remplir™ delivers superior nerve regeneration, earlier return to function, and higher quality tissue restoration compared to current surgical suture techniques.
June 18, 2025
Stockhead | Interview with Dr Ian Valerio
During his visit to Australia last week for Orthocell’s annual nerve repair and reconstruction symposium, US reconstructive surgeon Dr Ian Valerio made the time to speak with Stockhead’s Tylah Tully about the significant global opportunity for Remplir, following recent FDA approval.
June 2, 2025
Orthocell Receives Regulatory Approval for Remplir™ in Hong Kong
Orthocell has received regulatory approval from the Hong Kong Department of Health’s Medical Device Division to commence sales of Remplir™ in the Hong Kong nerve repair market.
May 12, 2025
The West Australian | Biotech’s easy cell to crack American market
An article in The West Australian has highlighted Orthocell’s rapid progress in securing 12 US distributors across 21 states for our flagship nerve repair product Remplir™.
May 12, 2025